Rapport Therapeutics, Inc.

RAPP
NASDAQBiotechnology

+98.5%

since IPO

IPO Price

$17.00

Current Price

$33.74

Return

+98.5%

Market Cap

$1.6B

IPO Date

Jun 7, 2024

Lockup End

Dec 4, 2024

Lockup Status

Lockup expired 511days ago

Price Performance

Stock price vs IPO price over time (sample data)

Stock Price
IPO Price
Lockup End

Performance Summary

First Day
N/A
1 Month
N/A
3 Months
N/A
6 Months
N/A
1 Year
N/A
Since IPO
+98.5%

Rapport Therapeutics, Inc. (RAPP) — IPO Analysis

By Kian O Connor | Updated 4/29/2026

Company Overview

Rapport Therapeutics, Inc. (ticker: RAPP) specializes in innovation initiatives while maintaining strategic capabilities in competitive advantages, positioning itself within the Biotechnology sector through strategic positioning and cost-effective alternatives. The company has developed its operations around customer satisfaction, creating market differentiation through specialized expertise and subscription-based recurring revenue that supports sustainable growth and customer relationship development. The company completed its public offering on 2024-06-07, accessing capital markets during economic environment adaptation within the Biotechnology landscape. The IPO timing reflected the company's strategic positioning and growth trajectory, with market reception emphasizing management's execution capabilities and the company's approach to innovation initiatives as key value creation drivers in an evolving competitive environment. Post-IPO trading performance has demonstrated strong market reception and sustained investor interest reflecting confidence in growth strategy execution. Market assessment focuses on the company's strategic positioning and strategic emphasis on competitive advantages as indicators of long-term competitive positioning within the Biotechnology sector, with investors evaluating operational execution and market opportunity capture relative to industry development trends. The lockup period expires May 13, 2025, providing market insights into management and early investor confidence in strategic direction and competitive positioning. Given the company's focus on innovation initiatives and emphasis on customer satisfaction, insider trading decisions will likely reflect assessments of execution progress, competitive dynamics, and growth opportunity realization within the evolving Biotechnology market landscape.

Performance Overview

Since going public at $17.00 per share on Jun 7, 2024, Rapport Therapeutics, Inc. shares have gained 98.5%, rewarding investors who participated in the IPO. The stock currently trades at $33.74, giving the company a market capitalization of $1.6B.

Lockup Expiration

The lockup period for Rapport Therapeutics, Inc. expired 511 days ago on Dec 4, 2024. Insiders and early investors are now free to sell their pre-IPO shares. The post-lockup trading period is often volatile as the market absorbs any additional supply from insider selling.

Industry Context

Rapport Therapeutics, Inc. operates in the Biotechnology sector, which has seen varied IPO activity in recent years. The company is headquartered in the United States and is classified under SIC code . Understanding the competitive landscape and sector dynamics is essential for evaluating the long-term prospects of any newly public company in this space. Investors should consider broader market conditions, sector-specific trends, and company fundamentals when assessing RAPP as an investment.

Trading History

Rapport Therapeutics, Inc. is actively trading in the public markets with a current share price of $33.74. The company went public at $17.00 per share, resulting in gains of 98.5% for IPO investors. With a current market capitalization of $1.6B, Rapport Therapeutics, Inc. continues to establish its presence as a publicly traded entity in the Biotechnology.

Important Disclaimer

This analysis of Rapport Therapeutics, Inc. (RAPP) is provided for informational purposes only and should not be construed as investment advice. All data is sourced from SEC EDGAR filings and public market feeds. Past performance is not indicative of future results. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions. IPOLockup.io is an independent research platform with no financial interest in any of the companies covered.

Insider Selling Activity

Estimated insider trading activity around lockup expiry period (sample data)

3
Pre-Expiry Average
Minimal
73
Expiry Day
High
58
Post-Expiry (30d)
High

Activity Heatmap

60 days before/after lockup expiry
Intensity Scale:
Minimal
Low
Moderate
High
Very High
Lockup Expiry

About This Data

This heatmap shows estimated insider selling activity based on typical patterns around lockup expiry periods. Actual data would be derived from SEC Form 4 filings. Higher intensity indicates more insider transactions, which may correlate with increased selling pressure and potential stock price volatility.

Related IPOs

TickerCompanyIndustryIPO DateIPO PriceCurrentReturn
EVMNEvommune, Inc.BiotechnologyNov 6, 2025$16.00$25.58+59.9%
MPLTMapLight Therapeutics, Inc.BiotechnologyOct 27, 2025$17.00$30.31+78.3%
LBRXLB Pharmaceuticals IncBiotechnologySep 11, 2025$15.00$31.38+109.2%
CURXCuranex Pharmaceuticals IncBiotechnologyAug 26, 2025$4.00$0.43-89.3%
CAICaris Life Sciences, Inc.BiotechnologyJun 18, 2025$21.00$18.44-12.2%
MENSJyong Biotech Ltd.BiotechnologyJun 17, 2025N/A$2.17N/A
AARDAardvark Therapeutics, Inc.BiotechnologyFeb 13, 2025$16.00$5.59-65.1%
SIONSionna Therapeutics, Inc.BiotechnologyFeb 7, 2025$18.00$39.59+119.9%

Related IPO Analysis

KO
By • Founder & Data Analyst